Price History
Investment Checklist
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Trend
Price below most MAs — downtrend | Bearish MA stack (20<50<200)
Price Action
Support & Resistance Levels
Volume Analysis
Stop Loss Levels
Fixed Risk
Technical Levels
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹477.5 Cr | ₹526.3 Cr | ₹559.1 Cr | ₹611.6 Cr |
| Net Profit | ₹58.3 Cr | ₹55.8 Cr | ₹54.2 Cr | ₹32.6 Cr |
| EPS | — | ₹22.33 | ₹21.69 | ₹13.04 |
| Operating Profit | ₹96.8 Cr | ₹92 Cr | ₹76.1 Cr | ₹51.4 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.4 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.5 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 23.0 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.4 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.3 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.6 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 26.1 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 91.5 | ₹83.02K Cr mid Cap | |
| AstraZeneca Pharma India Limited | ₹8,117.50 | +0.04% | 108.2 | ₹20.29K Cr small Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 18 Jul 2025 | Dividend - Rs 32 Per Share | DIVIDEND |
| 05 Jul 2024 | Dividend - Rs 24 Per Share | DIVIDEND |
| 14 Jul 2023 | Dividend - Rs 16 Per Share | DIVIDEND |
| 07 Jul 2022 | Dividend - Rs 8 Per Share | DIVIDEND |
| 18 Aug 2021 | Interim Dividend - Rs 2 Per Share | INTERIM_DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for ASTRAZEN
View All
AstraZeneca Pharma India closes trading window from June 16, 2026 - scanx.trade
AstraZeneca Pharma India closes trading window from June 16, 2026scanx.trade
AstraZeneca Pharma India gets CDSCO nod for expanded use of breast cancer drug Enhertu
The approval expands the eligible patient population for the therapy in India and allows AstraZeneca to market the drug for the additional indication, subject to any other required statutory clearances.
AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer
AstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its import, sale, and distribution for an additional use. The drug will now be available as a first-line treatment for certain types of advanced breast cancer. This development expands treatment options for oncologists and patients facing HER2-positive breast cancer.